The Individualized Medicine Biobank for Bipolar Disorder has built a community advisory board to help guide us in this critical early phase development. The identification of genetic risk factors associated with disease onset can potentially lead to early interventional treatment in at-risk patients. This is particularly important in Bipolar Disorder, as the onset of any treatment is often delayed by more than a decade and those individuals with the earliest illness onset generally have poor outcomes and the longest delays to first treatment.
Additionally, identification of pharmacogenomic predictors of treatment response could provide greater selectivity to treatment recommendations, as well as help prevent such serious adverse events as antidepressant induced mania.
The Bipolar Biobank is supported by a generous gift from a private benefactor.
© 2013 Mayo Foundation for Medical Education and Research. All rights reserved.